GLI1 and acute lymphoblastic leukemia: Notably, treating primary leukemic cells from patient T-ALL D15 harboring the pathogenic PTCH1 T1106M mutation with the FDA-approved SMO inhibitor vismodegib also effectively suppressed their viability and GLI1 expression [56].